← Back to updates
Emerging treatmentsResults from peopleSubgroup finding: significant in Hispanic or Latino participants, not significant in Black participants

Post hoc analysis of two completed Phase 3 trials in relapsing MS

OPERA trials: post hoc look at disability worsening in Black and Hispanic or Latino participants

Published by MyelinWatch:

What happened

Researchers led by the University of Southern California, with authors from Genentech, Roche and other US centres, re-analysed the OPERA I and II trials, which compared ocrelizumab with interferon beta-1a for two years in relapsing multiple sclerosis (MS). In the interferon group, non-Hispanic Black and Hispanic or Latino participants had a higher risk of disability worsening confirmed after 24 weeks, measured with a combined (composite) disability measure, than non-Hispanic White participants (hazard ratio 3.0 and 2.3). Non-Hispanic Black and Hispanic or Latino participants also had more CD19-positive B cells at the start. In 1,138 participants who consented to genetic analysis, higher African or Americas genetic ancestry was also linked to higher risk. Ocrelizumab lowered B cells in all groups. Compared with interferon, it lowered the risk of this composite disability worsening in Hispanic or Latino participants (hazard ratio 0.38; 95% confidence interval 0.20–0.72). In the 65 Black participants the estimate also pointed to lower risk (hazard ratio 0.41), but the 95% confidence interval of 0.13–1.29 includes no difference, so the result is not statistically significant.

What this means for people with MS

This is not a new treatment or a new approval: ocrelizumab is already an approved MS treatment. The analysis was done after the trials ended, in small subgroups (only 65 Black participants), using self-reported race and ethnicity; it cannot show why risk differed and does not change treatment guidance. The authors conclude that ocrelizumab reduced risk regardless of race or ethnicity, but for Black participants the study alone does not establish this. It does not support changing an individual treatment without a neurologist.

About the approach studied in this programme: OPERA I and II (ocrelizumab)

Ocrelizumab is an antibody that binds CD20 on B cells and reduces that immune-cell population. OPERA I and II compared this approach with interferon beta-1a for relapsing MS during the randomized period, then followed participants receiving ocrelizumab in an open-label extension; the extension is not a continuing randomized comparison.

Approach source: JAMA Neurology — original OPERA follow-up article ↗

What kind of evidence exists?
1,628 OPERA I and II participants by self-reported race and ethnicity: 65 non-Hispanic Black, 213 Hispanic or Latino and 1,350 non-Hispanic White
How reliable is this source?
Peer-reviewed article in Multiple Sclerosis Journal; only the published abstract was reviewed. Post hoc subgroup analysis of two randomised Phase 3 trials, funded by Roche, with authors from Genentech and Roche.
Source: Multiple Sclerosis Journal (SAGE) — peer-reviewed primary article ↗Source: Multiple Sclerosis Journal — DOI 10.1177/13524585261496124 ↗ Source: ClinicalTrials.gov — OPERA I (NCT01247324), completed with posted results ↗ Source: ClinicalTrials.gov — OPERA II (NCT01412333), completed with posted results ↗
Research event/source date
Published by MyelinWatch
Last substantive MyelinWatch update

Related substantive developments

Research event/source date:
Emerging treatmentsRegistered study in peopleRegistered study plan; no results

Registered Phase 1/2 study; not yet accepting participants; start estimated for January 2027

UKT-CART19.1: a CAR-T study in autoimmune diseases including MS was registered in Tübingen

Organisation: University Hospital Tübingen · Germany

ClinicalTrials.gov first posted NCT07932262 on 12 November 2026. The sponsor is University Hospital Tübingen in Germany. This is a single-centre, open-label Phase 1/2 study with one treatment group. It tests UKT-CART19.1, CAR-T cells made from the person's own T cells and aimed at CD19, a marker on B cells. The same treatment, given as one infusion, is tested in adults aged 18 to 80 with seven relapsed or treatment-resistant autoimmune diseases, one of which is multiple sclerosis (MS). People with MS must have had recent disease activity (a relapse, worsening or new MRI activity in the previous 24 months) and must not have responded to at least two high-potency MS medicines (category 3 in the German guideline). The registry estimates 36 participants in total for all diseases and does not say how many will have MS. The main outcome is safety over 6 months. The EU clinical trials register (CTIS) shows authorisation in Germany on 14 August 2026. ClinicalTrials.gov lists the study as not yet accepting participants, with an estimated start in January 2027.

Published by MyelinWatch:

What this means for people with MS

Registration and authorisation describe a study plan. They do not show that anyone has been enrolled or treated, or that UKT-CART19.1 works or is safe in MS, and no results are posted. The estimated start differs between the two records (recruitment from 1 July 2026 in CTIS, January 2027 on ClinicalTrials.gov), and neither shows that recruitment has begun. The study has one centre, in Tübingen, and neither record lists a site in Greece, so it is not an established route to treatment for people in Greece. Eligibility is decided by the study team, whose contacts are in the registry. Participants are to be followed for up to 15 years, as required for gene-therapy studies.

Research event/source date:
Emerging treatments + myelin repairRegistered study in peopleFirst participant dosed; no results posted

Combined early Phase 1/2a study in people; no results posted

PRO-1562: Progentos reports first participant dosed in an early study of a possible myelin-repair drug

Organisation: Progentos Therapeutics · United States

On 3 November 2026, Progentos Therapeutics announced that the first participant has been dosed in its Phase 1/2a study of PRO-1562 (NCT07826689), an experimental oral small molecule designed to repair myelin in multiple sclerosis (MS). The company did not give the dosing date or say in which part of the study this happened. It describes the Phase 1 part as placebo-controlled single rising doses in healthy adults at one site in Australia, so the announcement does not show whether that participant received PRO-1562 or placebo. The later Phase 2a part plans six months of once-monthly doses or placebo in adults with relapsing MS and chronic optic neuropathy. The company says that the drug promoted myelin repair in laboratory and animal studies; it reports no human results. The ClinicalTrials.gov record, last updated on 29 September 2026 and checked on 6 November, still shows the study as accepting participants, an estimated October 2026 start and no posted results.

Published by MyelinWatch:

What this means for people with MS

According to the company, this study has started dosing. That does not show that PRO-1562 is safe, that it repairs myelin in people or that it helps people with MS. Laboratory and animal results may not apply to people. The announcement does not establish that the MS part has opened. PRO-1562 is an experimental drug, not an available treatment. The registry lists one site, in Adelaide, Australia, and none in Greece. No established approved treatment in clinical practice has been proven to reliably restore myelin in MS.

Research event/source date:
Emerging treatmentsRegistered study in peopleStudy authorised in Greece; not a result

Phase 3 extension study authorised in Greece; recruitment not yet started

Frexalimab: Greece authorises the long-term Phase 3 extension study

Organisation: Sanofi · France

The EU Clinical Trials Information System (CTIS) shows that Greece authorised Sanofi's Phase 3 extension study LTS18002 (2026-525688-41-00) on 2 November 2026. Denmark, Portugal and Poland authorised it on the same day, after Belgium (30 October 2026) and Austria (1 November 2026); all six countries are listed as authorised with recruitment pending. The record plans 17 participants in Greece and lists four Greek hospitals: AHEPA University General Hospital of Thessaloniki, the University General Hospital of Ioannina, the General University Hospital of Larissa and the 401 General Military Hospital of Athens. The study will look at the long-term safety and tolerability of frexalimab, an experimental antibody, in people with multiple sclerosis (MS). It is open only to people who complete earlier frexalimab studies on the study drug, such as the Phase 3 studies FREXALT and FREVIVA. The estimated EU recruitment start is 15 February 2027.

Published by MyelinWatch:

What this means for people with MS

Authorisation means the study may proceed in Greece; it does not mean that it has started at any Greek hospital, that anyone has received treatment in it, or that frexalimab works. No Phase 3 results are available yet. People who are not already in a frexalimab study cannot join this extension, so it is not a way for other people with MS in Greece to receive frexalimab. Frexalimab is not an available treatment in Greece.